Supporting the

Neuroendocrine Cancer Community

Important CREON® Update

Apr 9, 2019

Mylan, the marketing authorisation holder for Creon, has decided to discontinue the manufacture and distribution of Creon 40K from June 2019. It’s important to note that this decision is not associated with any safety or efficacy findings. 

Why have Mylan discontinued Creon 40K?

Producing Creon 40K requires a different concentration of active enzymes which have been decreasing over the last few years. Because of this Creon 40K has experienced frequent supply constraints. 

Will I still be able to take Creon? 

Creon capsules are interchangeable and patients can achieve the higher dose by taking more of the lower strength capsules. Patients should not be concerned about the efficacy when switching to a lower strength capsule. 

We advise that you speak with your healthcare professional regarding transferring to a different strength capsule to achieve the required dose. 

Update regarding current stock 

A new delivery will be made by the end of the week commencing 8th April (25,000 unit capsules) with further deliveries scheduled for 18th & 22nd April. 

If you have any questions, please contact Mylan Medical Information: